After reviewing the competition, Piper Jaffray analyst Matt O'Brien does not believe competing technologies will have much of an impact on Intuitive Surgical until at least 2018. Even then, it is doubtful they will seriously impact Intuitive's top-line trajectory, the analyst tells investors in a research note. He points out that most of the competition are targeting general surgery and prostate cancer, which represent around 40% of Intuitive's cases per year. O'Brien keeps a Neutral rating on Intuitive Surgical shares with a $550 price target citing valuation.